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The7-valent pneumococcal conjugate vaccine (PCV7) produced a significant herd protection in unvaccinated adult population
mostly because of pneumococcus carriage decrease in vaccinated children. It is not known if the 13-valent pneumococcal vaccine
can give similar effect on adults. Aims of theworkwere to evaluate whether the 6 additional serotypes are present in nasopharynx
of children and serotype distribution in invasive pneumococcal infections (IPD) in adults.
Realtime-PCR was used to evaluate pneumococcal serotypes in adults with confirmed IPD and in nasopharyngeal swabs (NP)
from 629 children not vaccinated or vaccinated with PCV7 and resident in the same geographical areas. Two hundred twenty-
one patients (116males, median 67.9 years) with IPDwere studied (pneumonia nD 103, meningitis nD 61 sepsis nD 50, other n
D 7). Two hundred twelve were serotyped. The most frequent serotypes were 3, (31/212; 14.6%), 19A, (19/212; 9.0%), 12 (17/212;
8.0%), 7F, (14/212; 6.6%). In NP of children, the frequency of those serotypes causing over 50% of IPD in adults was very low,
ranging from 0.48% for serotype 7F to 7.9% for serotype 19A. On the other side serotype 5, very frequent in NP (18.7%) caused
<1% IPD.
In conclusion serotypes causing IPD in adults are very rarely found in children NP. We suggest that herd protection obtainable
with the additional 6 serotypes included in PCV13may bemore limited than that demonstrated with PCV7 in the past. In order to
reduce the burden of disease in adults, adults should be offered a specific vaccination programwith highly immunogenic PCV.
Introduction
Streptococcus pneumoniae is the most important cause of pneu-
monia and invasive bacterial infections in any age, with the great-
est incidence in children and elderly.1
More than 90 serotypes exist, but only a subset is associated
with invasive disease.2
Since its introduction in the United States in 2000, the 7-
valent conjugate pneumococcal vaccine (PCV7, including sero-
types 4,6B,9V,14,18C,19F,23F) has dramatically reduced
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invasive pneumococcal disease (IPD) both in vaccinated and in
unvaccinated age groups, through induction of herd protection.
3-7 The same effect was present, even though less evident, in
Europe where the decrease in adult IPD associated to PCV7 sero-
types was counterbalanced by a rapid increase in IPD due to non-
PCV7 serotypes.8-10
The herd protection obtained with PCV7 was hypothesized to
be due to the reduction in nasopharyngeal carriage of vaccine
strains in immunized children, with subsequent interruption of
transmission to their non-immunized contacts.11,12
In the pre-PCV7 era, the 7 serotypes included in PCV7, were
not only the most frequent serotypes causing IPD in children
and adults, but also the most frequently found in healthy carrier
children both in USA and in Europe.1-2,12-13 That situation is
present today in countries were PCV7 vaccination has never been
used.14
In Italy, as in other countries, PCV7 has been used up to 2010
and then substituted by PCV13, which includes the 6 additional
serotypes 1, 3, 5, 6A, 7F, 19A. While PCV vaccination is
included in the Vaccination Schedule for Italian children and
offered to all infants in Italy, no definite suggestion has been
given for adults, so that Italian regions follow different strategies,
with most regions giving no vaccination; at the same time possi-
ble advantages for adults obtainable through herd protection
given by infant vaccination are under debate. Actually no data is
available to demonstrate whether the 6 additional serotypes
included in PCV13 have a large presence in NP of children and
whether their elimination through PCV13 may have a significant
herd protection effect on adults.
The aim of the present study was therefore to evaluate the dis-
tribution of S.pneumoniae serotypes in adults with IPD and com-
pare it with the distribution of serotypes found in a large
population of healthy carrier children resident in the same geo-
graphical areas in order to evaluate whether PCV13 vaccination
of infants and children, reducing nasopharyngeal carriage, may
have the potential to reduce IPD burden in adults and offer, with
the use of PCV13 the same herd protection we have experienced
with PCV7.
Results
Diagnosis of IPD in adults
We identified a total of 221 patients with IPD including
pneumococcal pneumonia (n D 103; associated with sepsis in
12/103), meningitis (nD 61; associated with sepsis 14/61); sepsis
(n D 50), other IPD (peritonitis, arthritis, otomastoiditis n D 7).
Median and interquartile range (IQR) of age was 67.9 (51.9–
75.1) years. The gender ratio M/F was 116/105 (1.1).
Diagnosis of IPD was obtained using RT PCR directly on
normally sterile fluids (n D 93) or on culture isolates (n D 128).
IPD incidence increased with age as shown in Figure 1a. As
for the clinical presentation of IPD, pneumonia was the most fre-
quent IPD in any age group with the exception of the 31–45 y
group where sepsis and meningitis were more frequent (35.7%
each) (Fig. 1b).
Serotype distribution in IPD
Pneumococcal serotyping was obtained in 212/221 (96.0%)
patients using RT-PCR. In 128 cases, serotyping was performed
on culture isolates while in 93 cases serotyping was performed
directly on biological samples. All 128 isolates could be serotyped
using RT-PCR; IPD remained non-typeable in 9/93 biological
samples (9.7%), because of sample paucity.
The most frequent serotypes were 3 (31/212 14.6%), 19A
(19/212, 9.0%), 12 (17/212, 8.0%), 7F (14/212, 6.6%); sero-
type 12 was the most frequent serotype (7/14, 50.0%) in the class
of age 61–75 y.
Serotype distribution according to potential vaccine protec-
tion is shown in Figure 2. Percentage of IPDs due to one sero-
type potentially preventable with PCV13 were respectively
72.7%, 39.3%, 54.1%, 48.1%, 52.6% for the age classes 18–30,
31–45, 46–60, 61–75 or over 75.
Overall, potential serotype coverage on all age IPDs was
respectively 14.6% and 50.5% for PCV7 or PCV13. Others sero-
types, classified as not vaccine serotypes, caused 49.5% of IPDs.
No difference between serotype distributions was found in
patients with different clinical presentation.
Since in the areas under study PCV13 was included in the vac-
cination schedule in July 2010 in substitution of PCV7, we ana-
lyzed the 2 intervals of time as “pre-PCV13” (IPDs diagnosed in
Figure 1. Distribution of IPD cases (n D 221) according to age groups (A)
and clinical presentation (B).
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the 4 y interval 2007–2010) and “post-PCV13” (IPDs diagnosed
in 4 y time, 2011–2014). The percentage of IPDs due to one
serotype potentially covered by PCV13, was 55.5% in “pre-
PCV13” era and 48.9% in “post-PCV13” era (¡6.6%), while
non vaccine serotypes represented respectively 44.4% and 51,0%
(C6.6%) in the 2 periods; the difference was not statistically dif-
ferent (pD0.47; 95% CL 0.69–2.46). As for the single serotypes,
incidence of serotype 19A was 6/63 (9.5%) in pre-PCV13 and
13/149 (8.7%) in post-PCV13; serotype 7F incidence was
respectively 8/63 (12.7%) and 6/149 (4.0%) while serotype 3
increased from 6/63 (9.5%) in pre-PCV13 to 25/149 (38.9%) in
post-PCV13.
Nasopharyngeal carriage of streptococcus pneumoniae in
healthy children
Six-hundred and twenty-nine healthy children were included
in the study (262 from Friuli and 367 from Tuscany); mean age
was 24.4 months (median 20, IQR 9–37 months); 564/629
(89.7%) had been fully vaccinated, 3/629 (0.48%) were incom-
pletely vaccinated and 62/629 (9.9%) were not vaccinated.
Among the 564 fully vaccinated children, in 555/629 (88.2%)
vaccination was completed with 3 doses in the first year of life, in
6/629 (0.95%) vaccination started in the second year of life, in
3/629 (0.48%) after the second year of life.
In 315/629 NP swabs (50.1%) Streptococcus pneumoniae
was found and serotype distribution was evaluated. Two-hundred
and ninety-seven (297/315, 94.3%) NP samples were serotyped
while 18/315 (5.7%) were found positive for Streptococcus
pneumoniae but the serotype was not identified and were defined
as non-typeable. Multiple serotype carriage was found in 247/
297 (83.2%). Serotype distribution is shown in Figure 3a. Sero-
type 3, the most frequently found in adults with IPD, was
revealed in 7/315 (2.2%) Streptococcus pneumoniae positive NP
swabs, or 7/629 (1.1% ) of the entire pediatric population
studied; serotype 19A was
found respectively in 50/315
(15.9%) of the pneumococcus
positive NP swab or 50/629
(7.9%) of the pediatric popula-
tion; as for serotype 12, third in
frequency, causing 7.8% of
adult IPD, it was found only in
1 NP swab (1/315; 0.3% or
1/629; 0.16% of the pediatric
population) while serotype 7F,
fourth in frequency with 6.6%
of IPD, was found in 3/315
(0.95%) pneumococcus posi-
tive NP swabs or 3/629
(0.48%) of the entire pediatric
population studied. Overall,
serotype causing over 50% of
IPD in adults (3,19A, 12, 7F,
15, 22, 8, on the whole 54.7%)
were found in NP of healthy
children in 12.9% of cases.
The most frequent serotypes in NP swabs were serotype 35F
and 5, found respectively in 171/315 (54.3%) and in 114/315
Figure 2. Serotype distribution in 212 adults with invasive pneumococcal disease. PCV7 serotypes accounted for
14.6%, all PCV13 serotypes 50.5%, non vaccine serotypes 49.5%.
Figure 3. Comparison between pneumococcal serotypes found in naso-
pharyngeal swabs obtained from healthy carrier children and adults with
invasive pneumococcal disease expressed as percentages (A) and case/
carrier ratio (B).
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(36.2%) of pneumococcus positive NP swab that is in 171/629
(27.2%) and in 114/629 (18.1% ) of all children studied. Those
serotypes were detected respectively in 8 cases (3.6%) and 2 cases
(0.9%) of IPD in adults (1.1%). Case/carriage ratio is shown in
Figure 3b.
Evaluating separately serotypes that could be eliminated
through PCV13 vaccination, we found that serotypes 1,3,6,7F
and 19A, which represent 36.8% of IPD in adults, are not found
in more than 15% of NP. On the other side serotype 5, which is
very frequent in NP, reaching alone 18.7%, was found in IPD in
0.9% of cases.
Discussion
The present study, conducted on a large population of adults
in 2 Italian areas with high coverage of infant pneumococcal vac-
cination (PCV7 since 2006 and PCV13 since July 2010), is, for
our knowledge, the largest study on IPD in adults conducted in
Italy in the last 10 years, that is during the PCV7 and PCV13
era. The study confirms the progressive increase of IPD incidence
with increasing age in adults, with a peak in the age group of 61–
75 y. When evaluated in the whole period under study (2007–
2014) serotype distribution demonstrated a low proportion, less
than 15%, of IPDs due to PCV7 serotypes in all the age groups.
That figure is significantly lower than that demonstrated in Italy
in the pre-PCV7 era,15 so suggesting a herd protection for the
PCV7 serotypes obtained through infant vaccination.
The 6 additional serotypes included in PCV13 accounted for
a further 35%, while “non- vaccine” serotypes were found in
about 50% of cases. Serotypes 3 and 19A for the PCV13 group
and serotype 12 for the “non-vaccine serotypes” group were the
most frequent.
NP swabs were found positive for Streptococcus pneumoniae
in over 50% or healthy children included in the study, confirm-
ing our previous results.16 Over 80% children carried multiple
serotypes. That proportion is higher than previously described by
our group;16 the main reason is that 29 primers/probes were used
in the present work compared to 21 primer/probes in our previ-
ous works16,17 so allowing individuation of a large number of
serotypes. When comparison is done with studies performed by
other groups using cultural methods18 the difference is even
greater. Actually, since the serotyping methods based on culture
commonly require that only one or 2 colonies be tested, the
chance to find more than one serotype is limited.18 For the same
reason culture-based methods probably overesteem replacement
by non vaccine serotypes after vaccination.18 Our present and
previous16,17 studies, performed using serotyping methods based
on RT-PCR suggest that multiple non vaccine serotypes are com-
monly present in nasopharynx of healthy carriers
Our study suggests a low correspondence between serotypes
found in IPD in adults and serotypes found in nasopharyngeal
swabs of healthy carrier children with a very low incidence in NP
of those serotypes such as 1,3,7F and 19A causing most IPD in
adults. According to the design of the study, nasopharyngeal
swabs had been collected from children who could have been
vaccinated with PCV7 but not PCV13, in order to avoid
possible decrease in the incidence of the 6 additional serotypes
included in PCV13 because of vaccination. Nonetheless, even
though evaluated in the pre-PCV13 era, the most invasive sero-
types found in adults, such as serotypes 3, 7F and 19A, included
in PCV13, were very rarely found in nasopharyngeal swabs from
children.
That was not completely unexpected since it’s well known that
some serotypes have more frequently or exclusively an invasive
behavior while other are more commonly or exclusively found in
carriers.13 However this phenomenon assumes an important role
when carried serotypes are considered in relationship with herd
protection effect. Vaccine coverage was not even all over Italy at
the time the study started, in 2007, so that our results, obtained
in 2 regions with high vaccine coverage could not fit perfectly for
other regions. However, vaccine coverage has rapidly increased
over the following years exceeding 70% in the large majority of
Regions in the mid-term and reaching a mean coverage over
80% at the end of the study.19 Therefore we suggest the study
results can we applicable to all Italian Regions.
In the present study IPD in adults were evaluated in a larger
timeframe (2007–2014) compared to nasopharyngeal carriage
(2009–2010); however that difference does not affect study con-
clusions since serotype distribution in adult IPD is homogenous
all over the study period.
Experience on PCV7 in many countries in the world demon-
strated a strong herd-protection of adults when vaccine was
administered to children in the first year of life3,7,8,11,12,20 and it
has been suggested that herd protection is mainly due to the
reduction of NP carriage obtainable in children through vaccina-
tion.11,12 Actually the demonstrated herd protection effect of
PCV7 could be expected, since in the pre-PCV7 era, the 7 sero-
types 4,6B,9V,14,18C,19F and 23F were at the same time the
most commonly found in adult IPD and in NP of healthy chil-
dren13,14,15 so that their elimination trough vaccination could
significantly reduce bacterial diffusion and disease in non-immu-
nized cohorts.
The present situation, during the PCV13 era in Italy is quite
different, as suggested by our data. The 6 additional serotypes
included in PCV13 are very rarely found in NP. Therefore, even
though mass vaccination would succeed in eliminating
completely all the 6 additional serotypes from NP of healthy
carrier children, it would, altogether eliminate only the most rare
serotypes. It’s not clear how elimination of very rare serotypes
from NP might impact on disease diffusion in non-immunized
cohorts.
Moreover recent studies have demonstrated16,21,22 that PCV
is not able to eliminate carriage state forever probably because of
the physiological decrease in antibody titers, which remain high
enough to prevent invasive infections but not enough to prevent
carriage state. However even a transient elimination or a signifi-
cant decrease of vaccine serotypes from NP of carriers might have
an important impact on diffusion of the disease of some serotypes
and therefore on burden of disease in adults if the frequency of
those serotypes is high, as was the case of PCV7 serotypes in pre-
PCV7 era.13,14,15
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Our results, obtained in a large cohort of healthy children,
confirm16,23,24 that serotypes causing today IPD in adults in Italy
are very rarely found in carrier children. Serotype distribution is
not a stable state and modifies over decades. However, at present
it seems unlikely that vaccination of children with PCV13 can
strongly impact on disease burden of adults through carriage
reduction in Italy. Herd protection of adults through PCV13
might be therefore more limited than what previously described
for PCV7.
As for serotype 5, the second in frequency in nasopharyngeal
carriage in children, it has been demonstrated to be very rarely
cause of IPD in adults;13 our study confirm that over 10 y after
previous studies performed in Italy and Europe,3,15 serotype 5 is
still implicated in less than 1% of IPD in adults.
Therefore, even if vaccination could completely eliminate
serotype 5 from NP, IPD burden in adults in Italy would not be
influenced much by that change.
We are aware that, in the present cross-sectional study, we
considered serotype distribution in carriers as the only factor
affecting disease diffusion to unvaccinated population, however,
other variants such as duration of carriage25 seems to produce a
small impact on IPD rate.
In essence, the herd protection effect may result from a reduc-
tion in the transmission rate because of lowering the rates of colo-
nization or infection or both in the vaccinated population.26
Therefore, even if a partial herd protection will help reduce the
burden of adult IPDs in Italy through the reduction of IPD in
PCV13 vaccinated children, it is unlikely that herd protection
will occur because of a significant reduction of invasive serotypes
from NP of healthy children.
A limitation of the study is that IPD cases included may be
only a part of all IPD really occurred in the regions studied.
However we believe that cases we included may be representative
of serotype distribution in those geographical areas, since our
data set is the largest available in Italy, being even larger than that
obtained by the National Institute of Health through IPD
surveillance.
Cases in adults and elderly are undoubtedly the highest bur-
den for the society and cause the highest number of deaths due to
IPD, in Italy as in many other countries in the world. Therefore,
according to our results, in order to decrease disease burden,
adults should be offered a specific vaccination program with
available highly immunogenic conjugate vaccines since herd pro-
tection obtainable with the 6 additional serotypes included in
PCV13 could be more limited than that obtained with PCV7.
Patients and Methods
Adult Patients with IPD
The study included, within an active hospital-based surveil-
lance program, all adults >18 y with a confirmed diagnosis of
invasive pneumococcal disease in the period March 2007-Febru-
ary 2014. The study was performed in 2 Italian areas (Friuli-Ven-
ezia Giulia and Tuscany respectively in the North-East and
Center of Italy) where pneumococcal vaccine is offered to all
infants and vaccine coverage is >70% with a coverage of 74.9%
for Friuli and 93.5% for Tuscany in the most recent survey, in
2011.19
Invasive pneumococcal disease was defined as clinical suspi-
cion of bacterial disease (pneumonia, meningitis, sepsis, other )
and laboratory confirmation of the presence of S. pneumoniae in
a normally sterile fluid (blood, cerebrospinal fluid, pleural fluid,
peritoneal fluid) by Realtime-PCR and/or culture methods as
previously described.15,27
Healthy streptococcus pneumoniae carrier children
Retrospective analysis of nasopharyngeal carriage of Strepto-
coccus pneumoniae was evaluated in 629 nasopharyngeal swabs
obtained from healthy children 0–60 months of age from the
same geographical areas. Nasopharyngeal samples had been col-
lected within a 9 month-period in 2009–2010, immediately
before the introduction of PCV13.
Informed consent was obtained from all patients or guardians
before initiation of the study. The study was approved by the
local ethical committee.
Sample handling
Whole blood, and/or cerebrospinal fluid (CSF), and/or pleu-
ral fluid were collected from all patients as soon as possible after
hospital admission; isolates from blood or CSF-cultures were also
collected. Nasopharyngeal (NP) swabs were obtained as previ-
ously described.16
For culture purposes, 4–6 mL of blood samples (up to 3 sets)
were drawn and immediately sent to the local laboratory. Stan-
dardized procedures were used for collection and shipment of
blood samples to local laboratories. Samples for molecular tests
were sent at room temperature to the central Laboratory (Immu-
nology Laboratory, Anna Meyer Children’s University Hospital,
Florence, Italy) using an overnight freepost carrier; molecular
tests were performed within 2 h of delivery; for both diagnosis
and serotyping by Real Time PCR (RT-PCR), 200 mL of whole
blood, or CSF, or pleural fluid, or isolate (1 colony sampled in
1 mL of 0.9% NaCl) or liquid obtained from NP swab were
used.
Nasopharyngeal (NP) swabs were obtained from children as
previously described.16 The swabs were placed in tubes contain-
ing liquid Amies medium (Becton, Dickinson, Sparks, MD),
stored at 4C and sent to the laboratory on a weekly basis on ice.
NP samples were than aliquoted and stored at ¡20C. Only one
sample was obtained from each child so that there were not mul-
tiple samples from the same individual.
Diagnosis and serotyping of IPD
Diagnosis of laboratory confirmed IPD was based on RT-
PCR results for the lytA gene as previously described.17,27 A sam-
ple was considered negative if there was no increase in fluorescent
signal before cycle 40. Isolates already classified as S.pneumoniae
by cultural methods were also sampled and analyzed for the lytA
gene in order to confirm the diagnosis.
For serotyping, 33 primer/probe sets targeting different
regions of cpsA gene were used, specific for 33 different serotypes.
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Twenty-nine primer-probes set were previously published by our
group;17,27,28 the sequences of the 4 additional primer-probe sets
are available upon request. Same procedure was used for NP
swabs, as previously described.16,17
If no increase in fluorescent signal was observed after 40 cycles
for any of the serotype specific primer/probe sets in spite of a pos-
itive result with both RT PCR (lytA gene) and end-point PCR
(cpsA gene), the sample was considered non-typeable.
Pneumococcal serotypes were classified as PCV-7 or PCV13
serotypes if they were included in the 7-valent (4, 6B, 9V, 14,
18, 19F, 23F) or 13-valent (7-valent with the addition of 1, 3, 5,
6A, 7F, 19A) conjugate vaccine, respectively.
Definition of vaccination status
None of the IPD adult patients had received pneumococcal
vaccines (either conjugate or polysaccharide). As for carrier chil-
dren, data on pneumococcal vaccination status, including the
number of doses received and the timing, were taken from the
vaccination chart. The Italian vaccination schedule includes 3
doses of PCV in the first year of life or 2 doses between the first
and the second year of life, or a single dose after the second year
of life. Vaccine shift from PCV7 to PCV13 was done in July
2010. None of the children included in the study had received
PCV13.
As previously described16 children were considered completely
vaccinated if at the time of enrolling they had received 3 doses of
PCV7 and vaccination had been completed in the first year of
life or if they had received 2 doses of PCV7 in the second year of
life or one dose of PCV7 after the second year of life. Children
were considered incompletely vaccinated if they had started but
not completed the vaccination schedule.
Statistical analysis
Two tailed p values were used and p values <0.05 were con-
sidered statistically significant. Results were expressed as means
and standard deviations (SD) or as median and interquartile
range (IQR) as appropriate. x2 test was used to assess group dif-
ferences in categorical variables. Data were processed with the
SPSSX statistical package (SPSS 11.0, SPSS Inc., Chicago, IL).
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